DelveInsight, a leading market research and consulting firm, announces the release of its latest report, “KRAS Inhibitors Market Size, Target Population, Competitive Landscape and Market Forecast–2036.” The report provides a comprehensive analysis of KRAS inhibitors, including market trends, target patient populations, competitive landscape, emerging therapies, market forecasts, treatment dynamics, and opportunities across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
Key Takeaways from the KRAS Inhibitors Market
The KRAS Inhibitors market across the 7MM is projected to experience substantial growth during the forecast period 2022–2036.
The total KRAS Inhibitors market size in the 7MM was estimated at approximately USD 500 million in 2025 and is expected to reach nearly USD 7.8 billion by 2036.
The United States represents the largest KRAS inhibitors market and accounted for approximately 70% of the total 7MM market in 2025.
In the United States, the KRAS inhibitors market size was approximately USD 370 million in 2025 and is forecasted to reach nearly USD 7.2 billion by 2036.
Among key indications, Non-Small Cell Lung Cancer (NSCLC) represented the largest market opportunity, generating nearly USD 350 million in the US in 2025.
Estimated incident cases in the US during 2025 included approximately 207,000 NSCLC cases, 156,000 colorectal cancer cases, 63,000 pancreatic cancer cases, and 1,200 low-grade serous ovarian cancer (LGSOC) cases.
KRAS mutations were found in approximately 30% of NSCLC cases in the United States.
The KRAS G12C mutation remains the dominant therapeutic target in NSCLC, while KRAS G12D represents a major emerging opportunity, particularly in pancreatic cancer and ovarian cancer.
Leading KRAS inhibitors companies include Amgen, Bristol Myers Squibb, Roche/Genentech/Chugai, Revolution Medicines, Eli Lilly and Company, Merck, Taiho Pharmaceutical, Astex Pharmaceuticals, Cardiff Oncology, Elicio Therapeutics, Genfleet Therapeutics, Innovent, D3 Bio, and others.
Key approved therapies include LUMAKRAS/LUMYKRAS (sotorasib), KRAZATI (adagrasib), and AVMAPKI + FAKZYNJA Co-Pack (avutometinib + defactinib).
Keen to know more about the market? Request our sample page at KRAS Inhibitors Market Report.
https://www.delveinsight.com/sample-request/kras-inhibitors-market
Key Factors Driving the KRAS Inhibitors Market
Expanding Precision Oncology Adoption
The growing implementation of molecular diagnostics and biomarker testing has enabled earlier identification of KRAS mutations, expanding the eligible patient pool for targeted therapies and supporting broader adoption of KRAS inhibitors.
Success of KRAS G12C Inhibitors
The approval of LUMAKRAS and KRAZATI demonstrated that KRAS mutations are no longer considered “undruggable.” Their clinical success has accelerated investment and development activities targeting additional KRAS variants.
Growing Pipeline Beyond KRAS G12C
While current therapies primarily target KRAS G12C mutations, pharmaceutical companies are increasingly developing therapies targeting KRAS G12D, G12V, G12R, G13D, and pan-KRAS pathways, significantly expanding future market opportunities.
Increasing Cancer Burden Across Key Indications
The rising incidence of NSCLC, colorectal cancer, pancreatic cancer, and ovarian cancer continues to increase demand for effective targeted therapies, supporting long-term KRAS inhibitors market growth.
KRAS Inhibitors Competitive Landscape
The KRAS inhibitors market has evolved rapidly following the introduction of the first KRAS G12C inhibitors. LUMAKRAS (sotorasib) from Amgen and KRAZATI (adagrasib) from Bristol Myers Squibb currently represent the leading therapies for KRAS G12C-mutated NSCLC and colorectal cancer. Additionally, AVMAPKI + FAKZYNJA Co-Pack became the first approved therapy specifically for KRAS-mutated recurrent low-grade serous ovarian cancer in 2025.
The next wave of competition is expected from a robust pipeline of therapies including Divarasib, Daraxonrasib, Olomorasib, MK-1084, Onvansertib, DUPERT, ELI-002, D3S-001, ASP3082, IMM-1-104, and several pan-KRAS candidates. These therapies are being developed across multiple cancer indications and KRAS mutation subtypes.
Particular attention is being directed toward pan-KRAS inhibitors, which could potentially address broader patient populations compared to current mutation-specific therapies.
Discover more about therapies set to grab major KRAS Inhibitors market share @ KRAS Inhibitors Treatment Landscape.
Recent Developments in the KRAS Inhibitors Market
In January 2026, Merck initiated the Phase III KANDLELIT-007 trial evaluating MK-1084 plus KEYTRUDA for first-line treatment of KRAS G12C-mutant advanced or metastatic NSCLC.
In October 2025, Revolution Medicines announced that Daraxonrasib received Orphan Drug Designation from the US FDA for pancreatic cancer.
In September 2025, Eli Lilly announced that the US FDA granted Breakthrough Therapy Designation to Olomorasib plus KEYTRUDA for first-line treatment of KRAS G12C-mutated advanced or metastatic NSCLC.
In July 2025, Cardiff Oncology reported encouraging efficacy findings from the Phase II CRDF-004 trial evaluating Onvansertib in combination with bevacizumab and chemotherapy in RAS-mutated metastatic colorectal cancer.
In March 2025, Servier and Black Diamond Therapeutics entered a worldwide licensing agreement for BDTX-4933, expanding development efforts in RAF/RAS-mutant tumors.
What are KRAS Inhibitors?
KRAS inhibitors are targeted therapies designed to block oncogenic KRAS proteins that drive cancer cell growth and survival. KRAS is the most frequently mutated member of the RAS gene family and is implicated in several malignancies including non-small cell lung cancer, colorectal cancer, pancreatic cancer, and ovarian cancer. The development of KRAS-targeted therapies has transformed the treatment paradigm for patients with KRAS-driven cancers and continues to be one of the most active areas of oncology drug development.
KRAS Inhibitors Target Population Segmentation
The KRAS Inhibitors market assessment includes analysis of:
Total Incident Cases of NSCLC
Total Incident Cases of Colorectal Cancer
Total Incident Cases of Pancreatic Cancer
Total Incident Cases of LGSOC
KRAS Mutation Cases by Indication
KRAS Variant Distribution (G12C, G12D, G12V, G12R, G13D, and Others)
Treatment-Eligible Patient Population
Country-Specific Addressable Patient Pool
Scope of the KRAS Inhibitors Market Report
Assessment of Current and Emerging KRAS Inhibitors
Competitive Landscape and Pipeline Analysis
Market Dynamics, Drivers, and Barriers
KRAS Mutation Epidemiology and Patient Population Assessment
Market Size by Therapy, Indication, and Geography
Technology Assessment and Clinical Trial Analysis
SWOT Analysis and Competitive Benchmarking
KOL Perspectives and Analyst Insights
Market Access and Reimbursement Analysis
Pricing Trends and Market Forecasts Through 2036
To know more about KRAS Inhibitors companies working in the treatment market, visit @ KRAS Inhibitors Clinical Trials and Therapeutic AssessmentTable of Contents
KRAS Inhibitors Market Report Introduction
Executive Summary
Key Events and Market Developments
KRAS Inhibitor Market Overview
Disease Background and Clinical Significance
KRAS Mutation Epidemiology and Patient Population
Diagnostic Guidelines and Biomarker Testing
Current Treatment Landscape
Marketed Therapies
Emerging Therapies
Competitive Landscape Analysis
Conjoint Analysis
Market Outlook and Forecast
Market Access and Reimbursement
SWOT Analysis
KOL Views
Unmet Needs
Appendix
Report Methodology
Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
